A Glimpse Of Light For Kolon As US Invossa Trials To Resume
FDA Lifts Clinical Hold
Following the long-awaited decision from the US FDA, Kolon TissueGene will resume Phase III clinical trials of the cell and gene therapy for degenerative osteoarthritis TG-C (Invossa) in the US this year.
